'First Japanese Clinical Trial using Stem Cells’ isn’t and doesn't say Researchers

By Gareth Macdonald

- Last updated on GMT

‘Clinical Trial’ using ‘Stem Cells’ isn’t say Japanese Team
‘Clinical Trial’ using ‘Stem Cells’ isn’t say Japanese Team

Related tags Stem cells Stem cell Retina

Recent reports of a 'clinical trial' assessing 'stem cells' for the treatment of AMD are wrong say the Japanese researchers trying to transform somatic cells into retinal pigment epithelium (RPE) cells for transplant.

When news of the so called 'clinical trial' broke earlier this month most​ reports stated​ the project was first-of-its-kind effort focused on the development of stem cell-based treatments for patients suffering age-related macular degeneration (AMD).

The trouble is that this is not what is actually being done according to Dr Masayo Takahashi of the Riken Center for Developmental Biology and the Institute of Biomedical Research and Innovation Hospital in Kobe, Japan where the research is being conducted.

Dr Takahashi told BioPharma-Reporter.com the “immediate plan is not for a formal clinical trial that could be used to apply for marketing approval for a medical product​.”

Nor does the research involve harvested stem cells as has widely been reported​.

The protocol does not call for harvesting of stem cells from the patients. Instead, the patient's somatic cells will be reprogrammed into iPS cells [induce pluripotent stem cells], which will then be differentiated into retinal pigment epithelium (RPE) cells grown in sheets. RPE cells are affected in wet-type AMD, and the idea is to use these RPE cell sheets for autologous transplantation​.”


The team will grow the iPS cells using standard culture techniques in a dedicated facility according to Dr Takahashi, who added that: “As the planned study is not a clinical trial that would lead to a medical product approval, it is not conducted under manufacturing conditions​.”

Despite this, the team has taken great care to ensure it can select the most appropriate somatic cells continued Dr Takahashi, explaining that: “We perform a battery of quality assurance tests in collaboration with the Kyoto University Center for iPSC Research and Application​.”

Kyoto University made the headlines last year Dr Shinya Yamanaka, head of the research center, was awarded the Nobel Prize for his work on iPS cells.

Ultimately, Dr Takahashi’s team plan to transplant the cells into AMD patients as tissue grafts and are already working on a process to ensure that no iPSCs are included in the iPSC-derived RPE grafts intended for transplant.

Related news

Related products

show more

Trends in Biopharmaceutical Raw Material Selection

Trends in Biopharmaceutical Raw Material Selection

Actylis – The Partner of Choice | 31-Jan-2023 | Business Advice

Join us as our in-house experts, along with Cecile Bellamy from Pfizer, discuss current and future trends in biopharmaceutical raw material selection.

Liposomal and Nanoparticle Technology

Liposomal and Nanoparticle Technology

Pfizer CentreOne | 18-Nov-2022 | Technical / White Paper

Medical science is continuously searching for better ways to administer drugs into the body and to maximize the therapeutic effectiveness of the drugs...

Connectivity & Integration in Biomanufacturing

Connectivity & Integration in Biomanufacturing

Wheeler Bio | 17-Nov-2022 | Technical / White Paper

As the Pharma 4.0 initiative sets a new industry paradigm, more biomanufacturing companies are asking how they can design and build facilities that apply...

Scalability, Quality, and Speed with Transposons

Scalability, Quality, and Speed with Transposons

Wheeler Bio | 20-Oct-2022 | Technical / White Paper

To solve for the significant bottlenecks often presented by conventional cell line development processes, this article discusses how Wheeler Bio is leveraging...

Related suppliers

Follow us


View more